Gilead Sciences Inc (GILD)
64.78
-0.55
(-0.84%)
USD |
NASDAQ |
May 03, 16:00
64.79
+0.01
(+0.02%)
After-Hours: 20:00
Gilead Sciences Debt to Equity Ratio: 0.00 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 1.094 |
| September 30, 2023 | 1.120 |
| June 30, 2023 | 1.193 |
| March 31, 2023 | 1.202 |
| December 31, 2022 | 1.188 |
| September 30, 2022 | 1.196 |
| June 30, 2022 | 1.296 |
| March 31, 2022 | 1.315 |
| December 31, 2021 | 1.267 |
| September 30, 2021 | 1.290 |
| June 30, 2021 | 1.532 |
| March 31, 2021 | 1.592 |
| December 31, 2020 | 1.725 |
| September 30, 2020 | 1.679 |
| June 30, 2020 | 1.337 |
| March 31, 2020 | 1.092 |
| December 31, 2019 | 1.092 |
| September 30, 2019 | 1.193 |
| June 30, 2019 | 1.153 |
| March 31, 2019 | 1.211 |
| December 31, 2018 | 1.278 |
| September 30, 2018 | 1.195 |
| June 30, 2018 | 1.341 |
| March 31, 2018 | 1.411 |
| Date | Value |
|---|---|
| December 31, 2017 | 1.641 |
| September 30, 2017 | 1.178 |
| June 30, 2017 | 1.160 |
| March 31, 2017 | 1.288 |
| December 31, 2016 | 1.395 |
| September 30, 2016 | 1.605 |
| June 30, 2016 | 1.424 |
| March 31, 2016 | 1.703 |
| December 31, 2015 | 1.19 |
| September 30, 2015 | 1.276 |
| June 30, 2015 | 0.7536 |
| March 31, 2015 | 0.7196 |
| December 31, 2014 | 0.8041 |
| September 30, 2014 | 0.6936 |
| June 30, 2014 | 0.5907 |
| March 31, 2014 | 0.7323 |
| December 31, 2013 | 0.5836 |
| September 30, 2013 | 0.672 |
| June 30, 2013 | 0.6615 |
| March 31, 2013 | 0.7878 |
| December 31, 2012 | 0.8841 |
| September 30, 2012 | 1.020 |
| June 30, 2012 | 1.137 |
| March 31, 2012 | 1.289 |
| December 31, 2011 | 1.129 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2024
1.725
Maximum
Dec 2020
1.228
Average
1.199
Median
Debt to Equity Ratio Benchmarks
| Amgen Inc | 12.75 |
| CymaBay Therapeutics Inc (DELISTED) | 0.3735 |
| Bristol-Myers Squibb Co | 3.376 |
| Eli Lilly and Co | 2.046 |
| Xilio Therapeutics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 56.29B |
| Total Liabilities (Quarterly) | 38.84B |
| Shareholders Equity (Quarterly) | 17.46B |
| Current Ratio | 0.9796 |
| Net Debt Paydown Yield | 5.52% |